Immunosuppressive drug therapy for rheumatic disease

Area of Science:

• Rheumatology
• Immunology
• Nephrology

Background:

• Rheumatic diseases encompass a range of autoimmune and inflammatory conditions.
• Immunosuppressive agents are crucial in managing severe or refractory rheumatic diseases.
• Systemic vasculitis and lupus nephritis represent significant challenges in rheumatology.

Purpose of the Study:

• To review the efficacy of various immunosuppressive drugs in managing rheumatic diseases.
• To focus on recent advancements in treating lupus and systemic vasculitis.
• To evaluate the role of specific agents like cyclophosphamide and alkylating agents.

Main Methods:

• Literature review of studies on cyclophosphamide, chlorambucil, azathioprine, and 5-fluorouracil.
• Analysis of long-term data for lupus nephritis treatment regimens.
• Evaluation of controlled studies on immunosuppression for severe systemic vasculitis.

Main Results:

• Cyclophosphamide-containing regimens demonstrate efficacy in lupus nephritis.
• Renal biopsies are valuable predictors of outcome in lupus nephritis.
• Alkylating agents may benefit severe idiopathic membranous nephritis.
• Pheresis shows limited effectiveness in severe systemic vasculitis.
• Combination therapy with cyclophosphamide and prednisone improves disease control in vasculitis.

Conclusions:

• Cyclophosphamide is a key agent in managing lupus nephritis and systemic vasculitis.
• Treatment strategies for severe rheumatic conditions are evolving with immunosuppressive therapies.
• The combination of cyclophosphamide and prednisone offers improved outcomes for severe systemic vasculitis.